ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics. We have established long-term collaborations with big pharma like Pfizer, Novartis, and Johnson & Johnson, and well-known academic institutes.
To fight against COVID‑19, ACROBiosystems has been keeping a close eye on the continuing pandemic and are accelerating the development of SARS‑CoV‑2 protein antigens, antibodies, kits, and other related products to facilitate the development of serologic tests, therapeutic antibodies, and vaccines.
As the viruses is constantly mutating, new variants are expected to potentially increase the transmissibility and severity of COVID-19. ACROBiosystems is going full steam ahead on developing a collection of recombinant antigens for these emerging variants. The reagents can rapidly assess the efficacy of existing therapeutics and vaccines against the variants and enable the development of mutation-resistant antibodies and vaccine candidates/booster shots.
We would like to share the good news with you that ACROBiosystems has recently launched a ready-to-use neutralizing antibody titer serologic assay kit (Cat.No. TAS-K022) which can sensitively and specifically detect COVID‑19 neutralizing antibodies within 2 hours. The kit performance shows a high correlation with FDA-EUA approved ELISA kit!